Title
Category
Credits
Event date
Cost
Tweetorial: Subtle Symptoms of Tardive Dyskinesia Have a Huge Impact on Early Recognition and Intervention
  • Tardive Dyskinesia
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
In this Tweetorial learn the causes, signs and symptoms, assessments tools, and treatments for the medication-induced movement disorder tardive dyskinesia.
Improving Clinician Awareness of Rett Syndrome and Optimizing Management of Care Across the Patient Lifespan
  • Rett Syndrome
  • Child and Adolescent Psychiatry
  • Movement Disorders
  • Neurology
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Because of the multiple comorbidities associated with Rett syndrome, clinicians are advised to incorporate clinical guidelines that suggest implementing therapeutics with a multidisciplinary approach and with an eye toward new and emerging therapies. 
Tweetorial: Improving Clinician Awareness of #RettSyndrome and Optimizing Management of Care Across the Patient Lifespan
  • Rett Syndrome
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Because of the multiple comorbidities and symptoms associated with Rett syndrome, clinicians are advised to implement a multidisciplinary approach to disease management with an eye toward new and emerging therapies on the horizon.
Episode 1: Why the Duration Until Onset of Antidepressant Matters
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Pharmacology for MDD is limited by low efficacy, delayed response, and side effects. Research on the pathophysiology of the disease that includes the glutamatergic system and GABA signaling is ushering in a new era for rapidly acting antidepressants.
Episode 2: Update on Rapid-Onset Therapies for Major Depressive Disorder
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
The new fast-acting antidepressants esketamine, an NMDA receptor antagonist, and positive allosteric modulators of GABAergic neurotransmission brexanolone and zuranolone have created an important and exciting paradigm shift in the treatment of depression.
Tweetorial: A Rationale for Treating CKD with Combination Therapy
  • Renal Disease
  • Cardiology
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Clinicians have a number of therapeutic agents to choose from when treating T2D at risk of CKD. However, it's important to know how to sequence these therapies in real-world practice.
Parkinson's Disease Psychosis: Review of Neuropsychiatric Complications
  • Parkinson Disease
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
An average of 35% of patients diagnosed with Parkinson’s disease experience Parkinson’s psychosis. Recognition and diagnosis of this nonmotor manifestation is critical in choosing the best treatment strategy and managing these symptoms.
Tweetorial: CKD in Real-World Practice: Examine a Patient Case
  • Renal Disease
  • Cardiology
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Experts examine a patient case study as a way of translating guideline-based screening recommendations and current therapies that protect T2D patients from CKD progression in real-world practice.
Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
$0.00
Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.
Seizure Clusters in the Real World: The Call to Arms
  • Epilepsy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Treatment standards for neurologists and other clinicians caring for patients with epilepsy with emphasis on understanding epilepsy epidemiology, SUDEP and ILAE Classification updates, and therapeutic strategies.

Pages